Predicting response to endocrine therapy and survival in oestrogen receptor positive breast cancer is a significant clinical challenge and novel prognostic biomarkers are needed. Long-range regulators of gene expression are emerging as promising biomarkers and therapeutic targets for human diseases, so we have explored the potential of distal enhancer elements of non-coding RNAs in the prognostication of breast cancer survival. HOTAIR is a long non-coding RNA that is overexpressed, promotes metastasis and is predictive of decreased survival. Here, we describe a long-range transcriptional enhancer of the HOTAIR gene that binds several hormone receptors and associated transcription factors, interacts with the HOTAIR promoter and augments transcription. This enhancer is dependent on Forkhead-Box transcription factors and functionally interacts with a novel alternate HOTAIR promoter. HOTAIR expression is negatively regulated by oestrogen, positively regulated by FOXA1 and FOXM1, and is inversely correlated with oestrogen receptor and directly correlated with FOXM1 in breast tumours. The combination of HOTAIR and FOXM1 enables greater discrimination of endocrine therapy responders and non-responders in patients with oestrogen receptor positive breast cancer. Consistent with this, HOTAIR expression is increased in cell-line models of endocrine resistance. Analysis of breast cancer gene expression data indicates that HOTAIR is co-expressed with FOXA1 and FOXM1 in HER2-enriched tumours, and these factors enhance the prognostic power of HOTAIR in aggressive HER2+ breast tumours. Our study elucidates the transcriptional regulation of HOTAIR, identifies HOTAIR and its regulators as novel biomarkers of patient response to endocrine therapy and corroborates the importance of transcriptional enhancers in cancer.
Breast cancer diagnosis and prognosis is currently based on histological grade, disease stage (including lymph node status) and expression of hormone receptors (oestrogen receptor (ER), progesterone receptor (PgR) and ERBB2 (HER2)) (1). As breast cancer is a very heterogeneous disease and clinical outcomes can be highly variable, the predictive power of these markers is sometimes limited. The majority of ER+ patients receive tamoxifen or other forms of endocrine therapies, although many display or develop resistance, with a 33% recurrence rate after 5-years of tamoxifen treatment (2). Such endocrine resistance is common but difficult to predict (reviewed in Osborne and Schiff, 2011 (3)). Patients with HER2 positive tumours may be treated with Trastuzumab (Herceptin), however relapse in the form of metastasis is a regular occurrence (4). Thus, there is a clear and on-going need to identify additional prognostic and predictive molecular biomarkers that will augment traditional indicators and ultimately improve patient management and better predict response to therapies in these two types of breast cancer (5).
Gene transcription is regulated by a complex interplay of proximal and distal cis-acting regulatory elements, including promoters and enhancers, and trans-acting factors such as protein transcription factors (TFs) and non-coding RNAs. Whilst promoter elements lie proximal to the transcriptional start site (TSS) and are responsible for basal gene transcription, enhancers can be kilobases or megabases from the gene they regulate and are associated with cell- and tissue-specific expression (6,7). Disruption of enhancers through epigenetic or genomic aberrations can therefore impact cell identity, a key feature of tumourigenesis (reviewed in Kron et al., 2014 (8) and Herz et al., 2014 (9)) and so it is no surprise that these defects have been associated with cancer initiation and progression. For example, several breast cancer-associated SNPs map to enhancer elements bound by oncogenic transcription factors which regulate the expression of breast cancer susceptibility genes (10,11). Defects in the factors that mediate enhancer function have also been associated with cancer, including CTCF in breast and bladder cancer, and MED12 in prostate cancer. Enhancer elements and the factors controlling them therefore have significant potential to predict breast cancer progression (8,12,13).
Non-coding RNA genes are regulated at both the transcriptional and posttranscriptional level. Whole genome chromatin immunoprecipitation (ChIP) sequence analysis has shown that most miRNA promoters are over 1kb in length and map to distances up to 10kb from the miRNA sequence (14–17). The regulation of long non-coding RNA (lncRNA) genes is less understood, however it is now known that histone modification marks are associated with the regulatory elements controlling lncRNA gene expression (18). In addition, this analysis has revealed a distinctive methylation pattern around the transcription start site (reviewed in Venkatesh and Workman 2012 (19)), strong evolutionary conservation and binding sites for transcription factors that play a key role in cell proliferation and differentiation (20). Enhancers have emerged as crucial regulators of lncRNAs and their status is associated with the regulation of critical processes including the determination of cell fate and identity (7,21). These enhancer elements can bind a plethora of transcription factors and physically interact with gene promoters through chromatin looping to alter transcription (reviewed in Fraser 2006 (22)).
Hox antisense intergenic RNA (HOTAIR) is a lncRNA that has been implicated in chromatin remodeling and transcription. HOTAIR RNA associates with the polycomb repressive protein complex 2 (PRC2) (23), which is part of a vital poly-protein structure used to condense chromatin and effectively control transcription (24). HOTAIR regulates a wide range of genes, including HOXD genes, genes associated with epithelial-to-mesenchymal transition (EMT) and cell cycle regulation (25–27). HOTAIR is a marker of metastasis and poor prognosis in a range of cancers, including breast cancer (27), where it is overexpressed in a third of metastatic breast tumours (26). The ability of HOTAIR or its regulators to predict therapeutic response and outcome in ER and HER2 positive breast cancer has yet to be determined.
Several elements and factors controlling the transcriptional and post-transcriptional regulation of HOTAIR have been described and implicated in cancer (reviewed in Hajjari and Salavaty, 2015 (28)). At the transcriptional level, a proximal HOTAIR promoter has been identified approximately 1kb upstream of the HOTAIR TSS and several transcription factors have been shown to bind this region and regulate HOTAIR expression, including c-Myc (29), IRF1 (30), ERα (31) and MLL proteins. A susceptibility single nucleotide polymorphism (SNP) for esophageal squamous cell carcinoma (ESCC) and breast cancer has been found located within an enhancer in intron 2 of HOTAIR (32,33). In ESCC, the TT allele is associated with increased expression through higher enhancer activity. Methylation of proximal CpG islands mapping approximately 1kb downstream of HOTAIR have been associated with clinical and pathological features of breast cancer (34). The role of long-range regulation in the control of HOTAIR has not been reported and is the subject of this manuscript.
In this paper, we have elucidated the role of long-range regulation in the control of HOTAIR expression and explored the potential of long-range elements and factors to be valuable biomarkers for therapeutic response and outcome in breast cancer. Here, we report that FOX proteins can regulate HOTAIR, and can enhance its ability to stratify both HER2-enriched and ER+ breast cancer.
Identification of a distal enhancer downstream of the HOTAIR gene
To identify transcription control elements and factors that regulate HOTAIR expression in breast cancer cells, a chromatin state map for the HOXC locus housing the HOTAIR gene was generated using publically available data on evolutionary conservation, histone modification, ChIP-Seq and RNA-Seq. This analysis revealed a series of highly conserved regions that exhibit histone modifications and TF-binding densities suggestive of cis-regulatory activity (Figure 1A, higher resolution of the HOXC locus:
Of particular interest was a region located in a gene desert approximately 150 kb downstream of the HOTAIR TSS, marked by open chromatin (FAIRE-Seq), lysine mono-methylation (H3K4me1), RNA Polymerase II binding, as well as ER and PR binding, in multiple different breast cancer cell lines (Figure 1A). These marks are consistent with enhancer activity, and we therefore denoted this region as a putative distal enhancer, which we have termed HOXC Distal Enhancer (HDE). The enrichment of ERα and PgR binding at the HDE was associated with binding of FOXA1, a critical mediator of ER DNA binding in breast cancer cells. By interrogating ChIA-PET (Chromatin Interaction Analysis by Paired-End Tag Sequencing) data, we also found that the HDE engages in long-range interactions with the HOXC locus involving ERα, RNA Polymerase II and CTCF TFs (Figure 1B).
Mapping of enhancer-promoter interactions reveals an alternative promoter for HOTAIR
To investigate the interaction between the HDE and the HOTAIR promoter, chromosome conformation capture (3C) was performed. 3C libraries were generated for both ER+ (MCF7, ZR751) and ER- (MDA-MB-453 and MDA-MB-468) cell lines. Using the HindIII fragment containing the HDE as bait, 3C-qPCR relative interaction graphs were constructed for all fragments across the HOXC locus. In MCF7, ZR-751 and MDA-MB-453 cells, the HDE showed significant interactions with the HOTAIR start site (Figure 2A). Digestion with BglII effectively increased the resolution and revealed that the HDE interacts with two distinct regions within and upstream of the HOTAIR gene (Figure 2B). The first region corresponds to the promoter (P1) and the first intron of the canonical HOTAIR gene, and the second region, approximately 5kb upstream, corresponds to an alternate HOTAIR TSS, within intron-1 of HOXC11 (Figure 2C, alternative promoter cloned regions 1, 2 and 3, (ALT1, ALT2 and ALT3)). The alternate TSS is enriched for the histone mark H3K4me3 and RNA Polymerase II, suggesting bona fide promoter activity. The canonical HOTAIR promoter exhibits low levels of histone modifications that are suggestive of an active regulatory element (H3K4me3 and H3K27ac), perhaps suggesting a poised or inactive promoter in MCF7 cells. RT-PCR analysis demonstrated that an alternate longer form of the HOTAIR transcript is expressed in MCF7 cells originating from the alternative TSS (promoters ALT1-3) (
The putative enhancer augments HOTAIR promoter activity
To determine whether the HDE can enhance the transcription of genes at the HOXC locus, we generated luciferase reporter constructs by sub-cloning the HDE upstream of the HOXC10, HOXC11 or HOTAIR promoters (Figures 2D and E). These luciferase data support the RNA Pol II ChIA-PET and 3C interactions in that the HDE specifically interacts with and augments HOTAIR promoters (Figure 1B). In support of these findings, analysis of MCF7 RNA-Seq data clearly demonstrates RNA produced from the longer alternative HOTAIR transcripts (
To identify the active sequences of the HDE, we mutagenized the HOTAIR-HDE canonical promoter (P1) reporter construct (Figure 3A), and localized HOTAIR enhancer activity to a 114 base-pair region in MCF7 cells (between mutants 4 and 5; Figure 3B). Interestingly, this region contains several highly conserved, predicted transcription factor binding sites, including consensus binding sequences for forkhead box proteins (FOX Site 1 and 2) and AP1, which are associated with oestrogen-mediated transcriptional activity (Figure 3B). Consistent with this, analysis of ChIP-Seq data demonstrated that both c-Fos (part of the AP1 complex) and FOXM1 bind to the HDE (Figure 3C). Interestingly, in MCF7 cells c-Fos binding appears to be dependent on the presence of oestrogen. Binding of FOXM1, also in MCF7 cells, is decreased following the addition of the antibiotic thiostrepton (ThSt), which is known to prevent binding of FOXM1 to regulatory elements and chromatin. Furthermore, mutagenizing the sites in the context of the P1-HDE construct significantly reduced the enhancer activity of the HDE (Figures 2D and 3B).
HOTAIR is transcriptionally upregulated by FOX proteins
Given the role of FOX proteins in mediating enhancer activity of the HDE, we assessed the effect of FOXA1 and FOXM1 siRNA mediated knockdown on HOTAIR expression. FOXA1 and FOXM1 are key components of the ER signalling pathway in breast cancer and play important roles in disease progression, hence were prioritized for this study. This analysis showed a significant reduction in HOTAIR expression following knockdown of the FOX proteins (Figure 4A), suggesting that FOXM1 and FOXA1 positively regulate HOTAIR. In further support of these data, MCF7 cells treated with ThSt display significantly reduced the expression of HOTAIR and a known transcriptionally target of ThSt, FOXM1 (Figure 4B).
FOXA1 binds extensively throughout the HOXC locus (Figure 2A), we assessed gene expression changes of the locus following depletion of FOXA1 in MDA-MB-453 cells. All HOXC genes and the miRNAs MIR196A and MIR615 responded with reduction in expression following FOXA1 depletion except for HOXC4 (
HOTAIR is transcriptionally repressed by oestrogen
AP1, FOXA1 and FOXM1 facilitate the activity of oestrogen-mediated transcription in breast cancer.
Given the role of AP1, FOXA1 and FOXM1 in augmenting the activity of the HDE and that c-Fos binding to the HDE is oestrogen-dependent (Figure 3C), we investigated the effects of oestrogen on HOTAIR expression. We re-analyzed GRO-Seq data from MCF7 E2 treated cells; a sensitive, genome-wide run-on sequencing assay that maps the position, amount, and orientation of transcriptionally engaged polymerases. This analysis revealed that the amount of polymerase engaged with the HOTAIR alternative promoter (negative strand) decreased over time, with minimal engagement by 160 min post-E2 treatment (Figure 4C). Importantly, we found that HOTAIR (canonical transcript) levels in MCF7 cells decreased in response to E2 treatment, as determined by RNA-Seq and qRT-PCR analysis using two different TaqMan® Probes, that detect both the canonical and alternative isoforms (Figures 4D and E). These data suggest that oestrogen negatively regulates HOTAIR transcription.
HOTAIR expression is inversely correlated with oestrogen receptor signalling and directly correlated with FOXM1 in breast cancer
To investigate the relationship between HOTAIR and oestrogen signalling in breast cancer, we performed unsupervised hierarchical clustering of publically available (TCGA) breast cancer RNA-Seq data (Figure 5A). Given that numerous HOXC genes appear to be regulated by FOXA1 and possibly oestrogen, we clustered the expression of HOXC protein-coding genes, HOTAIR and known ERα cofactors. This analysis revealed a large cohort (Cluster 1 comprising 264 tumours and representing 49% of all cases) in which HOTAIR was inversely correlated with ESR1 and ERα cofactors: FOXA1, GATA3, GREB1, TLE3 and FOS (Figure 5A andFigure 5A,
HOTAIR and FOXM1 in combination predict response to therapy for ER+ tumours
Given the association between HOTAIR and FOXM1 expression and regulation of the HDE by FOX proteins, we sought to determine if these factors in combination may have prognostic potential in ER+ breast cancer. HOTAIR expression significantly stratifies the survival of patients with ER+ tumours and the combination of HOTAIR and FOXM1 expression increases this stratification (Figure 5B). FOXM1 alone is able to significantly stratify these tumours, however, the combination of HOTAIR and FOXM1 increased this stratification through an increase of the hazard ratio (Figures 5C and D).
HOTAIR and FOXM1 were also assessed for their potential to stratify patients on the basis of response to endocrine treatment and chemotherapy. Utilizing these biomarkers the RFS of patients treated with tamoxifen only (Tam), any endocrine therapy (ET) or the combination of endocrine and chemotherapy (CT) was stratified (Figure 5E). HOTAIR alone could only stratify survival of patients who received CT in combination with ET, where high expression associated with poor survival. FOXM1 alone is a significant biomarker for response to tamoxifen in these ER+ tumours, however HOTAIR + FOXM1 display the largest hazard ratio where patients with low expression have a 95% chance of survival beyond 10 years (Figures 5F and G). Taken together these data indicate that HOTAIR in combination with FOXM1 enhances the value of these genes as biomarkers to predict response to any of the therapeutic options, especially patients with aggressive ER+ tumours.
Given the intersection of HOTAIR transcriptional regulation and the oestrogen-signalling pathway, we hypothesized that HOTAIR plays a role in endocrine resistance. To explore this, HOTAIR expression was determined in MCF7-derived in-vitro models of oestrogen deprivation or anti-oestrogen resistance: MCF7X, TAMR and FASR. These cell line models were derived following prolonged in vitro oestrogen deprivation (MCF7X), tamoxifen treatment (TAMR) or fulvestrant treatment (FASR). HOTAIR expression levels were increased in MCF7X and TAMR cells (Figure 5H). In contrast, FASR cells had significantly less HOTAIR RNA. Together with HOTAIR, expression of ESR1, FOXM1 and FOXA1 were also altered, particularly in TAMR cells, which have decreased expression of ESR1 while maintaining expression of the FOX genes (Figure 5H). These data indicate that HOTAIR expression increases in cell line models of endocrine therapy resistance.
HOTAIR regulators enhance the power of HOTAIR as a biomarker in HER2-enriched tumours
To determine whether the prognostic potential of HOTAIR and FOXM1 coexpression applies to other breast cancer subtypes, HOTAIR levels were assessed across all of the intrinsic molecular subtypes of breast cancer. This analysis revealed significant enrichment of expression in the HER2-enriched subtype (Figure 6A). Both FOXA1 and FOXM1 are also highly expressed in this subtype, whilst ESR1 expression is depleted (Figure 6B). Interestingly, both HOTAIR and FOXM1 (HOTAIR + FOXM1) expression is significantly enriched in the basal-like and HER2-enriched subtype (
HOTAIR expression significantly stratified the RFS of patients with luminal B, HER2-enriched and ER+ tumours, with high expression associating with poor outcome (Figures 6C-E). This enhanced stratification is most evident in the more aggressive Grade 3 HER2-enriched tumours where HOTAIR + TFs expression significantly stratified the RFS greater than either HOTAIR or the TFs alone (Figures 6F–H). This stratification indicated that patients with low expression of HOTAIR + TFs, at the end of the studies, had a 93.75% chance of survival compared to 41.705% for the high expression group. These patients with dramatically worse survival are likely to respond poorly to therapies.
Collectively, we have identified several transcription factors that regulate the expression of HOTAIR and enhance the capacity of HOTAIR to predict the therapeutic response of patients with ER+ breast tumours and survival in breast cancer patients with HER2-enriched tumours.
Transcriptional enhancers enable precise regulation of gene expression, are frequently disrupted in cancer, and are emerging as the next generation of prognostic biomarkers for a range of human diseases. This study describes the long-range regulatory elements and factors controlling the transcription of HOTAIR in breast cancer. Further, we show that transcription factors correlated with HOTAIR expression in breast tumours are associated with poor prognosis.
In this paper, we have identified several novel transcriptional control elements regulating the expression of the lncRNA HOTAIR. These include an alternate promoter situated approximately 8 kb upstream of the previously described HOTAIR promoter, and a distal enhancer (HDE) located approximately 150 kb downstream of the HOTAIR gene. These elements are distinct from the core promoter and CpG elements described previously (29–31,34). We also show that the HOTAIR enhancer regulates HOTAIR expression by DNA looping and that this enhancer can augment the transcriptional activity of both the canonical and alternative promoter elements. Importantly we demonstrate that HOTAIR and its regulators, as identified through mapping of the HDE, combine to significantly stratify survival of breast cancer patients, supportive of previous work also demonstrating that enhancer activity and transcription factor binding align closely with clinical outcome (35). It would be worth exploring this aspect for the HDE, by utilizing ChIP-Seq, DNA accessibility assay or 3C data from tumours samples, it may be possible to stratify clinical response through activity of this enhancer.
Several studies have highlighted the promiscuous nature of promoter-enhancer interactions (36,37). To further the research presented in this study, it would be worth exploring the interaction landscape of the HOXC locus through 5C, a technique that looks at all interactions within a large genomic region (38). In addition to these experiments, mutagenesis of the HDE using a CRISPR/Cas9 approach would be valuable for further establishing the role of this enhancer (39,40). Such studies may shed more light on the interaction of the HOXC distal enhancer, the HOTAIR promoter and potentially other targets of this enhancer.
Reporter mutagenesis, ChIP-seq and siRNA experiments show that HOTAIR transcription is regulated by a number of breast cancer-associated transcription factors, including FOXA1 and FOXM1. FOXA1 is a crucial pioneer factor for ERα binding (41). FOXM1 has a wide variety of functions including regulating G2/M phase transition, mammary gland luminal progenitor cell maintenance, co-binding with ERα in cell lines, and is strongly implicated in the progression of multiple cancer types including breast cancer (42–43). FOXM1 expression has previously been linked with ERα activity and resistance to endocrine therapies, where elevated expression is correlated with poor prognosis (44, 45). Whilst the tumour expression data for HOTAIR, ESR1 and FOXM1 was consistent with in vitro results, this was not the case for HOTAIR and FOXA1. The latter may represent differences between the molecular environment in cell lines and tumours. The data presented here support an association between forkhead box proteins and HOTAIR expression, likely through direct transcriptional regulation.
Re-analyses of published ChIP-Seq data and oestrogen treatment in vitro demonstrate that oestrogen represses HOTAIR transcription. Our observations are consistent with recent finding by Xue et al. (46) indicating a direct association between ER and HOTAIR repression following oestrogen treatment in MCF7 cells. In support of our findings, there is a strong inverse correlation between HOTAIR and ESR1 expression in breast tumours, arguing against the notion of oestrogen enhancing HOTAIR expression. Our findings, and those of others (46), conflict with a previous report showing induction of HOTAIR expression by oestrogen (31). This discrepancy may reflect differences in experimental design, including time of oestrogen treatment and the method of transcript detection, or the use of a different sub-line of MCF7 cells.
We hypothesized that the association between oestrogen and HOTAIR may play a role in endocrine resistance. To explore this, we used the well-documented tamoxifen resistant, fulvestrant resistant and oestrogen independent sub-lines of MCF7 cells (48–51). HOTAIR expression increased in both the oestrogen-deprived MCF7X, and tamoxifen-resistant TAMR cells, concordant with a repressive role of oestrogen/ER signalling. Importantly, our previous work (Zhuang et al. 2014 (52)) also demonstrated that HOTAIR expression was significantly increased in a cell line model of resistance to induced cell death via TNF, which displays loss of ER and altered oestrogen signalling. These findings may be of clinical significance as they suggest therapies blocking oestrogen signalling may induce HOTAIR, which could in turn promotes breast cancer progression.
Endocrine therapy (e.g. tamoxifen, aromatase-inhibitors) is a standard of care for patients with HR+ breast tumours, but deciding which patients should be managed more aggressively by the addition of chemotherapy can be difficult (53). These patients are therefore a primary focus of prognostic and predictive biomarker development (54). It is highly significant that FOXM1 and HOTAIR co-expression significantly enhances the prognostic power of either factor individually in predicting relapse-fee survival in patients with ER+ and ER+/N+ breast cancer.
There are several pathways in which HOTAIR and FOXM1 are likely to collaborate in tumourigenesis, explaining their prognostic power. Although we have shown that FOXM1 regulates the expression of HOTAIR through the HDE, we acknowledge that their link in tumourigenesis may be through other means, such as a common functional pathway. FOXM1 is involved in cell cycle regulation (55,56) and the cyclin-dependent kinases CDK1 and CDK2 are known to phosphorylate EZH2 during S and G2 phases of the cell cycle (57), actively promoting EZH2-HOTAIR interactions (57). HOTAIR over-expression has also been implicated in cell cycle progression in pancreatic cancer (27). It is possible that FOXM1 and HOTAIR corroborate to regulate the aspects of the cell cycle, further work should aim to understand this, and if this functionality explains the prognostic potential of FOXM1 and HOTAIR in breast cancer.
FOXM1 has been implicated in chromosome instability (CIN), a process associated with aneuploidy, aggressive tumours and poor response to therapy (58–60). CIN, together with ER signalling, has recently been described as a powerful predictor of survival in ER+ patients (61). It is tempting to speculate that HOTAIR may play a role in the relationship between CIN and ER signalling. Reduced ER signalling (e.g. reduced oestrogen) may drive the expression of HOTAIR (via FOXA1 or FOXM1) possibly in association with increased expression of the CIN genes. This could explain the poor prognosis of subsets of ER+ tumours that appear genomically unstable and have reduced response to endocrine therapy (tamoxifen) alone or in combination with chemotherapy. It also raises the possibility that patients with ER+/N+ tumours who are resistant to endocrine therapy may benefit from anti-aneuploidy drugs that target molecules in the CIN module, such as TTK, AURK and PLK1 (62). Indeed, we have previously shown that oestrogen-deprived or deficient cells are more sensitive to CIN inhibitors (Stone et al. 2013 (50); Al-Ejeh et al. 2014 (61)).
We demonstrate that the expression of HOTAIR in concert with its transcriptional regulators, are informative in predicting outcome in HER2 breast cancer. Our findings support an earlier study indicating that HOTAIR is most highly expressed in the HER2-enriched intrinsic molecular subtype of breast cancer (63). The primary treatment for a patient with a HER2+ tumour is chemotherapy and Herceptin, a targeted monoclonal antibody to the HER2 receptor (64,65). Herceptin resistance is a significant clinical problem, resulting in lower RFS, and leading to poor disease outcome (66). The combination of HOTAIR and its long-range transcriptional regulators can better predict outcome in patients with high-grade HER2-enriched tumours. Use of these biomarkers, could immediately facilitate better targeting of expensive Herceptin treatment and improve patient surveillance. Longer term, inhibitors of this functional network could be investigated as targeted therapies.
The results presented describe a novel regulatory pathway controlling the expression of the lncRNA HOTAIR and show that the associated elements and factors can illuminate the mechanisms underlying the role of HOTAIR in breast cancer. This information can be used to identify novel biomarker combinations to better predict response to therapy and survival of breast cancer patients. Continuation of this work should aim at understanding the molecular mechanisms that explain the prognostication potential of HOTAIR and its regulatory elements, with particular relevance to endocrine therapy resistant tumours that have aberrant ER signalling and the relationship this may have to chromosome instability.
Materials and Methods
Cell lines; MCF7, T47D, ZR-751, MDA-MB-453 and MDA-MB-468; were cultured as per recommendations from ATCC. MCF7 cells were a kind gift from Chris Ormandy at the Garvan Institute of Medical Research (NSW, Australia) whilst T47D, ZR-751, MDA-MB-453 and MDA-MB-468 cells were sourced from ATCC. Estradiol (E2) treatment experiments followed a time course of 10 or 1 nM E2 across indicated time points within the text. Positive controls for the RNA-Seq and qRT-PCR experiments are shown in Figure S6. MCF7 cells, from which the endocrine resistant sublines were derived, were originally obtained from AstraZeneca. MCF7-derived acquired endocrine resistant sub-line RNA was sourced through A. Stone and J. M. W. Gee see author list for details. Tamoxifen-resistant (TAMR), fulvestrant-resistant (FASR), and oestrogen-deprived (MCF7X) derivatives were cultured as previously described (47,48,51). All cell lines were authenticated by short-tandem repeat (STR) profiling (Cell Bank, Australia) and cultured for less than 6 months after authentication.
Chromosome conformation capture (3C)
Chromosome conformation capture was performed as previously described by in Tan-Wong et al. 2008 (67–69). Briefly, cells were grown to 60–80% confluence and fixed with 1% formaldehyde. Libraries were generated for each cell line using HindIII and or BglII with control libraries undigested and unligated, representing native DNA without chromosome conformation. Any 3C-qPCR products were excluded if they amplified within the control libraries. GAPDH primers (amplified fragment contains no cut sites for these restriction enzymes) were used to determine the digestion and ligation efficiency for each library by comparing 3C-qPCR values to primers that amplifed a fragment containing a HindIII or BglII cut sites (Table S6). For each 3C-qPCR, primers were designed between 100–250 bp up or downstream of each HindIII cut site with the primer across the putative HOTAIR distal enhancer used as bait in each 3C-qPCR (70). 3C-qPCR conditions 50 °C, 2 min, 95 °C 10 min, (95 °C 15 sec and 60 °C 1 min) for 45 cycles. With a final melt starting at 50 °C 90 sec rising to 99 °C in 1 °C increments and 5 sec at each step. Each 3C-qPCR was performed on a pool of at least three independent libraries for each cell line and the qPCR done in duplicate. BAC controls were constructed following the protocol from (69) and primer pairs assayed for appropriate efficiency.
Cloning and luciferase reporter assays
HOTAIR enhancers and promoters were cloned into the luciferase reporter plasmid pGL3-Basic; see29). MCF7, T47D and MDA-MB-453 cells were transfected in antibiotic-free media with 700 ng of modified pGL3 promoter less reporter plasmids, 20 ng of Renilla and with 1μL of Lipofectamine® 2000 (Life Technologies, Grand Island, NY, USA). 48hours post transfection luciferase readings were measured using a DTX-880 luminometer and Dual-Glo® luciferase reporter kit (Promega, Madison, WI, USA), following the manufacturer’s recommended protocol. For oestrogen treatment and luciferase reporter levels of HOTAIR promoters and the HDE we followed the previously published method by Tan-Wong et al. (67).
Gene expression analysis
RNA for gene expression analysis was extracted using TRIzol® reagent (Life Technologies) and phenol-chloroform purified. RNA was then DNase I (Ambion, ThermoFisher) treated and cDNA generated using SuperScript® III (Invitrogen, ThermoFisher) using random hexamers supplemented with RNaseOUT™ (Invitrogen, ThermoFisher. Gene expression was assayed with TaqMan® probes (Life Technologies, ThermoFisher) following the manufacturer’s recommended protocol, probe list in71). Analysis of HOTAIR and FOXM1 expression in response to MCF7 cells treated with thiostreptin was sourced from GSE40767 (44). The probe sequence for HOTAIR expression on the array was as follows: TACACGCCTCTCCAAG ACAC AGTGGCACCGCTTTT CTAACTGGC AGCACA and FOXM1: GCCA CCTCCCCGTGTT TCCAAGTCAGCTTTC CTGCAAGAA GAA A T CCT GG. HOTAIR isoforms were sourced from public repositories for the RefSeq (72) and Broad (73) data sets. For analysis of HOTAIR and FOXM1 in the PAM50 subtypes, TCGA RSEM data was log2 transformed and mean-center normalized for all tumours, tumuor numbers as follows Basal-like (140, Basal), HER2-enriched (67, HER2), Luminal A (420, LumA) Luminal B (194, LumB) and Normal-like (24, N-Like).
Short-interfering RNA-mediated knockdown was performed using Flexitube siRNA (Qiagen). SiRNAs utilized in this study were FOXA1; SI04311888 and SI04217038 and FOXM1; SI04261831 and SI04166309 which were compared to the AllStars Negative Control (Qiagen). MCF7 cells were transfected using 3L of RNAi-Max (Life Technologies, ThermoFisher) and with a final concentration of 10nM for each siRNA. RNA was extracted and conversion into cDNA and subsequent qRT-PCR for gene expression as described above.
Bioinformatic analysis of publically available data
All data was sourced from public repositories and analyzed through the IGV browser and the human genome assembly Hg18 and/or Hg19, as indicated. Publically available data were sourced from the Gene Expression Omnibus (GEO). Accession codes for each dataset are listed in74).
The Cancer Genome Atlas (TCGA) (75) was accessed and analyzed through the University of California Santa Cruz (UCSC) Cancer Browser (75,76). HOTAIR + TFs were determined based on the average expression of HOTAIR, FOXM1, FOXA1, FOS together with the inverted average expression of ESR1. HOTAIR + FOXM1 is the combined average expression for these two genes.
The online tool, Kaplan-Meier Plotter (http://kmplot.com/analysis/) was used to produce survival curves based on gene expression with a maximum follow-up time of 10-years post diagnosis (77). High- and low-expression cutoffs were determined by the ‘Autoselect best cutoff,’ feature that determines the most significant stratification based on median, tertile or quartile splits. Kaplan-Meier Plotter uses logrank hazard’s ratios with corresponding P-values to determine significance. Probe IDs for each gene utilized in this analysis: HOTAIR (239153_at), ESR1 (205225_at), FOXA1 (204667_at), FOXM1 (202580_x_at) and FOS (209189_at).
Tumour clustering and correlations
Normalized TCGA (78) microarray expression data were used to cluster HOTAIR expression with ERα and ERα cofactors. The heat-map was produced using hierarchical average-linkage Manhattan-based clustering performed in Multiple experiment Viewer (MeV (79)) and Pearson correlation coefficients calculated for each comparison. The dendrogram tree cut point is indicated in Figure 5A, which creates 5 clusters of tumours, clusters 1-4 were grouped together based on the negative correlation between HOTAIR and ESR1 expression.
Western blot analysis
Total protein from MCF7 cells was extracted using RIPA buffer with 15 μg total per well and analyzed using Novex™ NuPAGE® gels from Life Technologies. Antibodies for FOXA1 and FOXM1 were ab23738 (Abcam, Cambridge, MA, USA) and sc-502 (Santa Cruz, Dallas, TX, USA) respectively.
Supplementary Material is available at HMG online.
We thank Jonathan Harris for the provision of DHT and David Miller for technical assistance and Kyle Upton for his critical review of the manuscript.
Conflict of Interest statement. None declared.
Research was funded by the National Breast Cancer Foundation (NBCF: 2007003445 and CG-12-07) of Australia, the Australian Research Council (ARC: DP0985025), the Cancer Council of Queensland (CCQ: 1026095) and The University of Queensland. DHD was supported by a Collaborative Program Grant from the, National Breast Cancer Foundation [NBCF; CG-08-03]. Institute, Integrative Cancer Biology Program U54CA1113001 (KPN). SLE, JDF, AMS and ED are supported by Fellowships from the NBCF [ID# ECF-10-05, ECF-12-04, ECF-12-12 and ECF-13-04 respectively]. FA is supported by Future Fellowship from the Australian Research Council [ID: FT130101417]. JMWG is funding by a Scientific Fellowship from Breast Cancer Now. MJM and JAB are supported by an Australian Postgraduate Award (APA). AS was supported from NBCF program grant. SJC supported by NHMRC fellowship. Funding to pay the Open Access publication charges for this article was provided by The University of Queensland.
- gene expression
- transcription, genetic
- biological markers
- breast neoplasms
- cell line
- genes, erbb-2
- receptor, erbb-2
- receptors, estrogen
- transcription factor
- breast cancer
- endocrine therapy
- transcriptional control
- enhancer of transcription
- binding (molecular function)